Romidepsin

CAS No. 128517-07-7

Romidepsin ( FK228, Depsipeptide )

Catalog No. M11164 CAS No. 128517-07-7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 139 In Stock
5MG 224 In Stock
10MG 404 In Stock
25MG 583 In Stock
50MG 830 In Stock
100MG 1125 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Romidepsin
  • Note
    Research use only, not for human use.
  • Brief Description
    Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM, respectively.
  • Description
    Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM, respectively.(In Vitro):Romidepsin (0-72 hours; 0-80 nM) inhibits proliferation of HCC cells in dose-dependent manner.Romidepsin (0-48 hours; 0-60 nM) leads to a time- and dose-dependent induction of cell cycle arrest in the G2/M phase in HCC cells.Romidepsin (0-48 hours; 0-60 nM) promotesapoptosis in HCC cells, increases c-caspase-3, c-caspase-9, and c-PARP protein expression.(In Vivo):Romidepsin (intraperitoneal injection; 0.5 and 1 mg/kg; every 3 day; 21 days) inhibited the tumor growth, reveals a higher expression of p-cdc25C, ki67, c-caspase-3 and c-PARP, and a lower expression of Ki-67 in Romidepsin treated tumors .
  • In Vitro
    Cell Proliferation Assay Cell Line:HCC cells Concentration:0 nM; 10 nM; 20 nM; 30 nM; 40 nM; 50 nM; 60 nM; 70 nM; 80 nM Incubation Time:0 hours; 12 hours; 24 hours; 48 hours; 72 hours Result:Inhibited HCC cells proliferation.Cell Cycle Analysis Cell Line:HCC cells Concentration:0 nM;15 nM; 30 nM; 60 nM Incubation Time:12 hours;24 hours; 48 hours Result:Caused a G2/M arrest.Western Blot Analysis Cell Line:HCC cells Concentration:0 nM;15 nM; 30 nM; 60 nM Incubation Time:12 hours;24 hours; 48 hours Result:Increaesd c-caspase-3, c-caspase-9, and c-PARP expression in HCC cells.
  • In Vivo
    Animal Model:Nude mice with Huh7 cells Dosage:0.5 and 1 mg/kg Administration:Intraperitoneal injection; 0.5 and 1 mg/kg; every 3 day; 21 days Result:Suppressed tumor growth in mouse xenograft models.
  • Synonyms
    FK228, Depsipeptide
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HDAC1| HDAC2
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    128517-07-7
  • Formula Weight
    540.7
  • Molecular Formula
    C24H36N4O6S2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mg/mL (18.49 mM)
  • SMILES
    O=C([C@H](C(C)C)NC(/C(N1)=C/C)=O)O[C@](CC(N[C@H](C(C)C)C(N2)=O)=O)([H])/C=C/CCSSC[C@]2([H])C1=O
  • Chemical Name
    (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(1methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16ene-3,6,9,19,22-pentone

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Furumai R, et al. Y Res, 2002, 62(17), 4916-492
molnova catalog
related products
  • MPT0G211

    MPT0G211 is a novel potent, selective HDAC6 inhibitor with IC50 of 0.291 nM.

  • SB-379278A

    A potent and selective HDAC8 inhibitor with IC50 of 0.5 uM.

  • SBHA

    SBHA (suberohydroxamic acid) is a Histone deacetylase (HDAC) inhibitor. HDAC is required for transcriptional modulation, cell cycle regulation and development.